Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) reported robust financial results for the half-year ended June 30, 2026, with group revenue rising 22% year-over-year to US$477 million. This performance tracks in line with the upper end of its full-year guidance of US$950 million to US$970 million.

Adjusted EBITDA surged 146% to US$52 million, supported by solid commercial execution across its product portfolio and an initial non-refundable payment of US$40 million from its strategic collaboration with Regeneron. Profit after tax stood at US$38 million, compared to a loss of US$2 million in the prior period.

Financial Performance

The company’s gross margin improved by 2 percentage points to 55%, while the Precision Medicine segment achieved a 65% gross margin, up 1 percentage point year-over-year. These improvements reflect favorable product mix and operational efficiencies.

Research and development investment totaled US$124 million, primarily directed toward late-stage therapeutic and precision medicine programs. Operating cash flow was positive at US$23 million, and the company maintained a cash balance of US$252 million as of June 30, 2026.

Segment Highlights

The Precision Medicine segment saw revenue grow 27% year-over-year, driven by volume growth and market share gains for Illuccix and Gozellix. Adjusted segment EBITDA for this division rose 26% to US$132 million.

In Telix Manufacturing Solutions (TMS), total segment revenue reached US$146 million, comprising US$89 million from third-party sales and service fees. The segment reported an operating loss of US$33 million, including US$10 million in depreciation and amortization on acquired intangibles.

Balance Sheet and Pipeline Progress

Telix completed the refinancing of its existing convertible bond structure, issuing US$600 million of new convertible bonds due 2031. Finance costs for the period were US$19 million, predominantly related to this refinancing.

Clinical milestones included:

• Patient enrollment nearing completion for the Phase 3 BiPASS study of Illuccix and Gozellix.
• FDA acceptance of the New Drug Application for Illuccix in China.
• FDA clearance for Pixclara Phase 3 IND application to explore indication expansion to brain metastases diagnosis.
• First patient dosed in LUTEON, a pivotal trial of TLX250-Tx in advanced clear cell renal cell carcinoma.

What the Numbers Show

The profitability turnaround is heavily influenced by non-operational items. While operating profit increased from US$10 million to US$46 million, the reported profit after tax of US$38 million includes US$40 million in other income from Regeneron. Without this one-time payment, the underlying operational profit would be significantly lower, highlighting the dependency on collaboration milestones for near-term bottom-line strength despite strong top-line growth.

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) will release its financial results for the half-year ended June 30, 2026 on Thursday, August 20, 2026. The Melbourne-based radiopharmaceutical company scheduled the disclosure to provide investors with timely updates on its commercial franchise and late-stage therapeutic pipeline progress during the first half of the year.

An investor webcast and conference call will be held immediately following the release at 9:00 a.m. AEST on August 20, 2026 (7:00 p.m. EDT on Wednesday, August 19, 2026). Participants can register for the webcast or teleconference via the link provided in the company’s official announcement. The event allows management to address questions regarding the financial performance and operational developments reported in the filing.

Reporting Timeline

The following table outlines the key dates for the Half-Year 2026 results announcement:

Business Context

Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company advancing targeted theranostics to improve outcomes for people with cancer. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. The company’s commercial franchise is anchored by its prostate cancer imaging portfolio, including Illuccix, which is commercially available in 22 countries including the U.S., and Gozellix, which is approved by the U.S. Food and Drug Administration (FDA).

The company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx in prostate cancer, TLX101-Tx in recurrent glioblastoma, and TLX250-Tx in kidney cancer. These assets are complemented by a deep pipeline of next-generation candidates. Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America, and Asia-Pacific.

Regulatory Disclosures

The announcement has been authorized for release by Telix Pharmaceuticals Limited’s Company Secretary, Shomalin Naidoo. The company notes that the information contained in the announcement is not intended to be an offer for subscription, invitation, or recommendation with respect to securities of Telix Pharmaceuticals Limited in any jurisdiction, including the United States. Forward-looking statements included in the announcement involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from any future results expressed or implied.